Lixte Biotechnology Holdings (LIXT) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Graphic logo of Lixte Biotechnology Holdings (LIXT)

The market price action for Lixte Biotechnology (LIXT), a lean oncology pharma company featuring a flat management structure and an option system, as visualized on the GURU.Markets platform for analytical convenience, demonstrates the 0.00 indicator. The business focuses on developing protein phosphatase inhibitors, including the promising LB-100, while expanding its partnership with the NCI to combat tumor resistance. The company is currently actively conducting clinical trials for agents designed to enhance the efficacy of chemotherapy for solid tumors.

LIXT Lixte Biotechnology Holdings Inc.: Enterprise Value to Operating Income Before Depreciation in the range 11/23/2025 - 07/06/2026

LIXT (lixte.com): analytical breakdowns and indicator data

- stock price and consensus target price:
Stock Quotes Lixte Biotechnology Holdings|LIXT - Fair Value Consensus
- market capitalization indicators:
Market Value Lixte Biotechnology, Inc.|LIXT - Total Enterprise Value
- book value of equity indicators:
Net Assets per Single Share Lixte Biotechnology|LIXT - Accounting Capitalization|Market Capitalization to Book Value Ratio lixte.com|LIXT - Cumulative Company Assets
- debt and liquidity data:
Debt to Equity Lixte Biotechnology|LIXT - Long-Term Liabilities to Capital|Short-Term Debt to Equity Lixte Biotechnology Holdings, Inc.|LIXT - Company Debts|Debt to Book Capitalization Ratio Lixte Biotechnology, Inc.|LIXT - Long-Term Debt|Company Short-Term Debts Lixte Biotechnology|Quick Liquidity Indicator lixte.com
- business earnings and investment ratios data:
LIXT - Company Net Income|Future Profit Lixte Biotechnology|LIXT - Company Value to Net Income|Projected Price to Earnings Lixte Biotechnology|LIXT - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Lixte Biotechnology, Inc.|LIXT - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Lixte Biotechnology|LIXT - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months lixte.com|LIXT - Earnings per share increase in current year|Earnings growth forecast for next year Lixte Biotechnology
Summary company analytics:LIXT (Lixte Biotechnology Holdings)
Original product of Lixte Biotechnology Holdings, Inc.

Lixte Biotechnology's development of antitumor drugs relies on scientific potential and patent protection, rendering the business resilient to macroeconomic cycles. The company's EV/EBITDA trajectory demonstrates the ratio of enterprise value to operating profit, allowing investors to assess the payback period for liabilities and determine the asset's fundamental margin of safety through the lens of capital intensity.

Competitor analysis

Incyte Corp. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation HCM|NUVB - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA dayonebio.com|Monopar Therapeutics Inc. (MNPR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation INBX|IMAB (I-Mab Biopharma Co., Ltd.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Fennec (FENC)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Heron Therapeutics (HRTX)|NVCT - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Coherus BioSciences Inc. CHRS|Corbus Pharmaceuticals Holdings, Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CRDF - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA BeyondSpring Inc|BCAB: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Citius Pharmaceuticals, Inc. CTXR|Enterprise Value to EBITDA Ratio CLRB|Company Value to EBITDA BioLineRx Ltd BLRX|Enterprise Value to EBITDA Ratio CANF (Can-Fite BioPharma, Ltd.)|APRE (aprea.com) - Business Value to Operating Income Before Depreciation|Kazia Therapeutics Limited - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio SLXN (Silexion Therapeutics Corp.)|NuCana Corp - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation CMRX (Chimerix Inc.)|CYCC: EV/EBITDA Multiple|Company Value to EBITDA G1 Therapeutics (GTHX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Kronos Bio, Inc.|KTRA: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ONCT|EV/EBITDA Multiple Portage Biotech Inc (PRTG)